Metastatic Spinal Cord Compression (MSCC)

1. Clinical Overview

Summary

Metastatic Spinal Cord Compression (MSCC) is a devastating oncological emergency occurring in 5-10% of all cancer patients, representing one of the most time-sensitive conditions in oncology and spinal surgery. It is defined as compression of the spinal cord or cauda equina by direct metastatic tumor extension, vertebral collapse, or epidural metastatic deposits. The most common primary malignancies are Breast, Lung, Prostate, Kidney, and Thyroid (mnemonic: "BLT with a Kosher Pickle"). [1,2]

The cardinal presenting symptom is pain (present in 83-95% of cases), which characteristically precedes neurological deterioration by weeks to months. This pain is often nocturnal (worse at night due to venous engorgement and biological tumor activity) and mechanical (exacerbated by movement or weight-bearing in cases of spinal instability). Early diagnosis is critical: ambulatory status at the time of diagnosis and treatment is the single strongest predictor of post-treatment functional outcome. [3,4]

Management involves immediate administration of high-dose corticosteroids (dexamethasone 16mg), strict spinal precautions with flat bed rest and log-roll transfers until stability is confirmed, and urgent MRI of the entire spine (mandated within 24 hours by NICE guidelines). Definitive treatment involves either surgery (separation surgery with posterior stabilization) or radiotherapy (conventional external beam or stereotactic body radiotherapy), guided by the NOMS framework (Neurologic, Oncologic, Mechanical, Systemic assessment). [5,6]

Key Facts

• The "Golden 24 Hours": NICE Guidelines (CG75) mandate MRI within 24 hours of clinical suspicion, with definitive treatment initiated within 24 hours of radiological confirmation. [7]
• The "BLT with a Pickle": Primary sources - Breast (21%), Lung (14%), Thyroid (rare but classic), (K)idney (8%), Prostate (15%). Together these account for > 60% of MSCC cases. [8]
• SINS Score: The Spinal Instability Neoplastic Score (0-18 points) objectively assesses whether the spine is mechanically stable. Unstable spines (SINS > 13) require surgical stabilization, not radiotherapy alone. [9]
• Ambulatory Preservation: 85% of patients who are ambulatory at treatment remain ambulatory, versus only 35% of non-ambulatory patients regain walking ability. [10]
• Skip Lesions: 30% of patients have non-contiguous vertebral metastases at multiple levels, mandating whole-spine imaging rather than limited MRI. [11]

Clinical Pearls

"Pain is the warning shot": 90% of patients experience back pain for a median of 7 weeks before developing motor deficits. In any cancer patient, new or worsening back pain should trigger urgent spine imaging. The pain often has unique characteristics that distinguish it from degenerative pathology. [12]

"The Night Watch Sign": Degenerative back pain typically improves with recumbency. Metastatic pain characteristically worsens at night (biological tumor activity, venous congestion, loss of muscle tone allowing micromotion at unstable segments). Patients often report "I can't lie flat" or "I have to sleep in a chair." [13]

"Assume Instability Until Proven Otherwise": Until spinal stability is formally assessed by imaging and SINS scoring, treat every suspected MSCC patient with strict spinal precautions (flat bed rest, log-roll transfers, hard collar for cervical lesions). Injudicious handling of an unstable spine can precipitate catastrophic neurological deterioration. [14]

"The Bilsky Grade Determines Urgency": Epidural spinal cord compression (ESCC) is graded 0-3 on MRI. Grade 3 (spinal cord compression with deformation) requires emergency intervention within hours, not days. [15]

"Steroid Timing Matters": Earlier administration of dexamethasone correlates with better neurological outcomes. Give 16mg immediately upon clinical suspicion, even before imaging confirmation. [16]

---

2. Epidemiology

Incidence and Prevalence

Metastatic spinal cord compression occurs in 5-10% of all cancer patients during their disease course, with autopsy studies suggesting occult spinal metastases in up to 40% of patients with advanced malignancy. The annual incidence is approximately 20,000-30,000 cases in the United States. [17,18]

Among patients with known vertebral metastases (detected on staging imaging), approximately 10-20% will develop symptomatic MSCC requiring intervention. The lifetime risk varies substantially by primary tumor type, ranging from 5% for lung cancer to 15% for breast cancer and prostate cancer. [19]

Demographics

• Age Distribution: Peak incidence occurs in the 6th and 7th decades, mirroring the age distribution of common solid organ malignancies. Median age at presentation is 65 years. [20]
• Gender: Slight male predominance (55% male, 45% female) reflecting the contribution of prostate and lung cancer.
• Spinal Level Distribution:
  • Thoracic spine: 60-70% (most common due to longer segmental length and proximity to venous drainage from common tumor sites)
  • Lumbosacral spine: 20-30%
  • Cervical spine: 10-15%
  • Multiple non-contiguous levels: 10-40% (varies by primary tumor type) [21]

Primary Tumor Distribution

The relative frequency of primary tumors causing MSCC has shifted over recent decades due to changing cancer demographics and improved systemic therapies prolonging survival:

1. Breast Cancer: 21% (most common overall, reflects high prevalence and prolonged survival with bone metastases)
2. Lung Cancer: 14% (second most common, often presents as initial manifestation)
3. Prostate Cancer: 15% (predominantly lytic variant in castrate-resistant disease)
4. Renal Cell Carcinoma: 8% (characteristically highly vascular, prone to pathological fracture)
5. Multiple Myeloma: 6-8% (can present with plasmacytoma causing isolated compression)
6. Lymphoma: 5% (usually high-grade NHL, exquisitely radiosensitive)
7. Unknown Primary: 10-15% (MSCC may be the initial presentation of occult malignancy)
8. Other: Melanoma, thyroid, sarcoma, GI malignancies (each less than 5%) [22]

Risk Factors for MSCC Development

Among patients with known metastatic bone disease, certain factors increase MSCC risk:

• Vertebral body involvement > 50%: Increases fracture and retropulsion risk
• Posterior element involvement: Direct epidural extension pathway
• Lytic lesions: Higher fracture risk compared to blastic lesions (exception: breast cancer mixed lesions)
• Pedicle destruction: Destabilizes the vertebral column ("winking owl sign" on AP radiograph)
• Previous vertebral fracture: Indicates mechanical instability and progressive kyphosis
• Rapid tumor growth: Renal cell, melanoma, thyroid have higher propensity for acute presentation [23]

---

3. Pathophysiology

Mechanisms of Spinal Metastasis

Hematogenous Spread via Batson's Venous Plexus: The most common mechanism. Batson described a valveless, low-pressure venous plexus surrounding the spinal column that communicates with thoracic, abdominal, and pelvic venous systems. Tumor emboli bypass portal and caval circulation, directly seeding vertebral marrow. This explains the predilection of prostate, breast, and lung cancers for spinal metastases. [24]

Direct Extension: Paraspinal tumors (neuroblastoma, lymphoma, sarcoma) can extend through neural foramina into the epidural space without bony involvement.

Arterial Hematogenous Spread: Less common, but accounts for brain and spinal cord parenchymal metastases (distinct from MSCC).

Cerebrospinal Fluid Dissemination: Leptomeningeal carcinomatosis (rare cause of cauda equina syndrome).

Mechanisms of Cord Compression

MSCC develops through four main pathomechanical pathways:

1. Direct Posterior Extension from Vertebral Body (85%)

The tumor originates in the vertebral body (vascular marrow space), grows through the posterior cortex, and extends into the epidural space, compressing neural elements anteriorly. This is the classic "anterior compression" pattern seen in breast, prostate, and lung metastases. [25]

2. Vertebral Collapse with Retropulsion (10-15%)

Pathological fracture through a lytic metastasis causes posterior displacement of bone fragments or entire vertebral body into the spinal canal. This creates acute angular kyphosis and sudden neurological deterioration. Common in renal cell carcinoma and melanoma due to aggressive bone destruction. [26]

3. Progressive Kyphotic Deformity (5-10%)

Multiple adjacent level involvement or significant vertebral height loss creates progressive sagittal plane deformity. The spinal cord is stretched over the apex of the kyphosis, causing venous congestion, ischemia, and axonal injury even without direct mechanical compression. [27]

4. Posterior Element Extension (5%)

Tumor arising in or spreading to the pedicles, lamina, or facets can grow directly into the spinal canal, causing posterior or lateral compression. This is less common but may occur with lymphoma or direct extension from paraspinal masses. [28]

Molecular and Cellular Pathophysiology of Cord Injury

Mechanical Compression: Direct pressure on the spinal cord causes:

• Venous congestion: Thin-walled epidural veins collapse first, causing venous hypertension
• Arterial insufficiency: Arterial supply compromised at higher compression pressures
• Axonal injury: Direct mechanical deformation disrupts axonal transport and myelin integrity
• Glial cell death: Oligodendrocytes and astrocytes undergo apoptosis [29]

Vasogenic Edema: Tumor compression disrupts the blood-spinal cord barrier, causing extracellular fluid accumulation that propagates rostral and caudal to the compression site. This is the target of corticosteroid therapy. [30]

Inflammatory Cascade: Compressed neural tissue releases pro-inflammatory cytokines (IL-1, IL-6, TNF-α) that exacerbate edema and secondary injury. [31]

Ischemia-Reperfusion Injury: Prolonged compression followed by decompression can paradoxically worsen injury through free radical generation and calcium-mediated excitotoxicity. [32]

Spinal Instability: The SINS Framework

The Spinal Instability Neoplastic Score (SINS) quantifies mechanical stability based on six parameters (0-18 points): [33]

SINS Interpretation:

• 0-6: Stable (radiotherapy safe)
• 7-12: Indeterminate (requires surgical consultation)
• 13-18: Unstable (requires surgical stabilization)

Validation studies demonstrate 95% inter-observer reliability and strong correlation with clinical outcomes. [34]

---

4. Clinical Presentation

Symptom Spectrum and Timeline

MSCC typically evolves through a predictable clinical progression, though tempo varies by primary tumor biology:

Phase 1: Pain Phase (Weeks to Months)

• Incidence: Present in 83-95% of patients at diagnosis
• Character: Deep, boring, aching pain localized to the affected vertebral level
• Nocturnal exacerbation: Pathognomonic feature distinguishing from degenerative disease
• Mechanical component: Worse with coughing, sneezing, Valsalva (increased epidural pressure)
• Percussion tenderness: Highly specific sign - direct palpation or percussion over spinous process elicits severe pain [35]

Phase 2: Radicular Pain (Days to Weeks)

• Thoracic: "Band-like" pain wrapping around chest or abdomen at dermatomal level
• Cervical: Radiating pain into shoulders, arms, hands (often mistaken for rotator cuff pathology)
• Lumbar: Sciatica-like pain radiating into buttocks and legs
• Indicates nerve root compression as epidural disease extends laterally through neural foramina [36]

Phase 3: Motor Weakness (Hours to Days)

• Onset: Typically insidious ("my legs feel heavy"), but can be sudden with pathological fracture
• Pattern: Symmetric, progressive, ascending weakness
• Severity: Ranges from subtle difficulty climbing stairs to complete paraplegia
• Rate: Critical prognostic indicator - rapid progression (ambulatory to non-ambulatory in less than 48h) indicates high-grade compression requiring emergency surgery [37]

Phase 4: Sensory Changes (Hours to Days)

• Ascending sensory level: "Numbness creeping up my legs"
• Sensory ataxia: Wide-based gait due to proprioceptive loss
• Paresthesias: "Pins and needles" below compression level
• Note: Sensory level may be several segments below the actual anatomic compression due to laminar architecture of spinothalamic tracts [38]

Phase 5: Autonomic Dysfunction (Hours)

• Bladder retention: Inability to void, palpable distended bladder (late sign, poor prognosis)
• Bowel incontinence: Loss of voluntary sphincter control (very late sign)
• Sexual dysfunction: Erectile dysfunction, loss of ejaculation
• Presence of sphincter dysfunction indicates > 50% cord compression and correlates with less than 30% chance of ambulation recovery [39]

Physical Examination Findings

General Inspection:

• Cachexia (advanced malignancy)
• Kyphotic deformity (visible gibbus deformity indicates severe vertebral collapse)
• Abnormal gait (wide-based, spastic, circumduction)

Spinal Examination:

• Percussion tenderness: Firm percussion over spinous processes elicits severe localized pain (sensitivity 60%, specificity 92% for vertebral metastasis)
• Palpable step-off: Indicates fracture-subluxation
• Paraspinal muscle spasm: Protective splinting

Neurological Examination:

Motor:

• Upper motor neuron pattern (cord compression above L1):

  • Spastic weakness (increased tone, velocity-dependent)
  • Hyperreflexia (brisk deep tendon reflexes)
  • Clonus (sustained ankle clonus > 5 beats)
  • Babinski sign (upgoing plantar response)
  • Loss of superficial abdominal reflexes (T6-T12 compression)

• Lower motor neuron pattern (conus medullaris L1-L2, cauda equina below L2):

  • Flaccid weakness (reduced tone)
  • Hyporeflexia or areflexia (absent ankle jerks in S1 radiculopathy)
  • Fasciculations (rare)

Sensory:

• Pinprick sensory level: Tested in midclavicular line on anterior chest/abdomen
• Proprioception: Impaired joint position sense (posterior columns)
• Vibration: Decreased tuning fork perception (also posterior columns)
• Perianal sensation: S2-S5 dermatomes (must be tested in all suspected cases)

Autonomic:

• Post-void residual: Bladder scan showing > 100mL retention
• Rectal examination: Decreased sphincter tone, absent anal wink reflex (S2-S4)
• Bulbocavernosus reflex: Absent (indicates conus/cauda involvement)

Functional Assessment:

• Ambulatory status: Key prognostic indicator (document: independently ambulatory, ambulatory with aids, non-ambulatory but can stand, wheelchair-bound, bedbound)
• Frankel Grade (neurological impairment scale):
  • A: Complete motor and sensory loss
  • B: Sensory only, complete motor loss
  • C: Motor useless (can move but cannot overcome gravity)
  • D: Motor useful (can overcome gravity, cannot resist resistance)
  • E: Normal [40]

Atypical Presentations

Cauda Equina Syndrome: Lumbar/sacral MSCC below L2 presents with:

• Asymmetric leg weakness (lower motor neuron)
• Saddle anesthesia (perianal numbness)
• Bladder/bowel dysfunction (early feature, unlike cord compression)
• Reduced/absent ankle reflexes
• Often confused with non-malignant cauda equina syndrome; cancer history is key [41]

Cervical MSCC: Unique features:

• Quadriparesis (all four limbs)
• Respiratory compromise (C3-C5 phrenic nerve involvement)
• Lhermitte's phenomenon (electric shock down spine with neck flexion)
• Hoffmann sign (finger flexion with middle finger flicking)
• Inverted radial reflex (C5-C6 lesions) [42]

Brown-Séquard Syndrome: Rare (5%) with lateral epidural extension:

• Ipsilateral motor weakness and proprioceptive loss
• Contralateral pain and temperature loss
• Suggests unilateral pedicle or lateral mass involvement [43]

---

5. Investigations

Imaging Modalities

MRI Whole Spine: Gold Standard

Indications: Any cancer patient with new/worsening back pain, neurological symptoms, or radicular pain. [44]

Protocol:

• Sequences required:
  • T1-weighted (anatomy, marrow signal, epidural fat)
  • T2-weighted (cord signal, CSF, edema)
  • STIR (Short Tau Inversion Recovery - suppresses fat, highlights edema and tumor)
  • T1 + Gadolinium (enhances tumor, distinguishes from post-treatment fibrosis)
• Field of view: Entire spine (craniocervical junction to sacrum)
• Rationale for whole spine: 30-40% of patients have multiple non-contiguous metastases; limited imaging misses treatable disease [45]

Timing: NICE CG75 mandates MRI within 24 hours of clinical suspicion. Delays beyond 24h correlate with worse neurological outcomes. [46]

MRI Findings:

• Vertebral body metastasis: Abnormal T1 hypointensity (replaces normal bright marrow fat), T2/STIR hyperintensity
• Epidural tumor: Soft tissue mass displacing epidural fat, compressing thecal sac
• Cord compression: Deformation of spinal cord with T2 signal change (edema/ischemia)
• Pathological fracture: Vertebral height loss, retropulsion, kyphotic angulation
• Paraspinal extension: Tumor beyond vertebral confines (indicates advanced local disease)

Bilsky Epidural Spinal Cord Compression (ESCC) Grade: [47]

• Grade 0: Bone involvement only, no epidural disease
• Grade 1a: Epidural impingement, no cord deformation
• Grade 1b: Cord abutment, no deformation
• Grade 1c: Cord deformation without T2 signal change
• Grade 2: Cord compression with T2 signal change but CSF visible
• Grade 3: Complete block, no CSF visible around cord

Grade 3 = Surgical Emergency (requires intervention within hours, not days)

CT Spine: Second-Line

Indications:

• MRI contraindicated (pacemaker, metallic foreign body, severe claustrophobia)
• Surgical planning (bone detail for instrumentation)
• Assessment of bone quality for cement augmentation

Limitations:

• Poor soft tissue contrast (cannot visualize spinal cord, epidural tumor)
• Underestimates degree of cord compression
• Misses purely epidural metastases without bone involvement

Utility: Superior for:

• Fracture pattern assessment (burst vs compression)
• Pedicle screw trajectory planning
• Bone density (blastic vs lytic lesions)

Plain Radiographs: Obsolete for MSCC Diagnosis

Do NOT wait for X-rays. NICE guidelines explicitly state: "Do not request plain radiographs if metastatic spinal cord compression is suspected." [48]

Why?:

• Sensitivity only 60% (misses 40% of significant lesions)

• 50% vertebral body destruction required for radiographic visibility

• No information about cord compression
• Delays definitive MRI imaging

Rare acceptable use: Standing lateral X-rays to assess kyphotic deformity alignment (after MRI confirmation, for surgical planning).

PET-CT: Staging and Primary Identification

Indications:

• Unknown primary tumor (10-15% of MSCC cases)
• Staging of known oligometastatic disease (considering aggressive local therapy)
• Assessment of systemic disease burden (influences prognosis scoring)

Utility: FDG-avid lesions identify primary tumor in 30-40% of unknown primary cases. [49]

CT Chest/Abdomen/Pelvis: Primary Tumor Search

Indications: MSCC with no known cancer history (MUO - Malignancy of Unknown Origin).

Diagnostic yield:

• Lung cancer: Identified in 70% of cases with chest CT
• Renal cancer: Identified in 85% with abdominal CT
• Overall primary identification: 60-70% with CT CAP [50]

Laboratory Investigations

Essential Baseline Tests

• Full Blood Count: Anemia (marrow infiltration, chronic disease), thrombocytopenia (marrow replacement)
• Renal Function: Baseline for contrast imaging, nephrotoxic chemotherapy
• Liver Function: Hepatic metastases, paraneoplastic syndrome
• Calcium: Hypercalcemia in 10-30% (particularly breast, lung, myeloma, renal) - drives additional treatment decisions [51]
• Inflammatory markers: CRP/ESR (elevated in infection mimics, e.g., epidural abscess)

Tumor-Specific Markers

• PSA (Prostate-Specific Antigen): Screen for prostate cancer in males with lytic bone lesions
• Serum/Urine Protein Electrophoresis: Multiple myeloma (monoclonal band, Bence-Jones proteinuria)
• CEA (Carcinoembryonic Antigen): GI malignancies
• CA 19-9: Pancreatic cancer
• CA 125: Ovarian cancer
• AFP/β-hCG: Germ cell tumors (rare spinal mets but important in young patients)

Tissue Diagnosis

CT-Guided Biopsy: Consider when:

• Unknown primary AND systemic imaging (CT CAP, PET-CT) non-diagnostic
• Solitary spinal lesion in patient without known cancer (could be primary bone tumor, infection, lymphoma)
• Need for tissue diagnosis to guide systemic therapy (particularly lymphoma vs carcinoma distinction)
• Suspected radiation-resistant histology requiring upfront surgery

Intraoperative Frozen Section: If proceeding to emergency surgery without tissue diagnosis, send specimens for:

• Frozen section (immediate preliminary diagnosis)
• Permanent histology
• Immunohistochemistry (identifies primary site in 70% of unknown primaries)

Avoid needle biopsy if:

• Diagnosis will not change management (emergency decompression required regardless)
• Known primary with typical radiographic appearance of metastasis

---

6. Management Algorithm

NICE CG75 Pathway (UK National Guideline)

                 SUSPECTED MSCC
        (Cancer History + Spinal Symptoms)
                        ↓
           DO NOT WAIT FOR PLAIN X-RAY
                        ↓
         ┌──────────────┴──────────────┐
         ↓                             ↓
   IMMOBILISATION                DEXAMETHASONE
(Flat Bed / Log Roll)          (16mg IV/PO STAT)
 Hard Collar (C-spine)          Then 8mg BD × 3d
         ↓                             ↓
   SPINAL PRECAUTIONS              PPI COVER
 (No sitting/standing)        (Omeprazole 20mg OD)
         ↓                             ↓
         └──────────────┬──────────────┘
                        ↓
                   URGENT MRI
                 (WHOLE SPINE)
                  less than 24 HOURS
                        ↓
              COMPRESSION CONFIRMED?
                        ↓
           ┌────────────┴────────────┐
          NO                        YES
           ↓                          ↓
    Alternative Dx          ALERT MSCC SERVICE
    - Disc prolapse         (MDT Coordinator)
    - Spinal stenosis              ↓
    - Muscle spasm          DEFINITIVE TREATMENT
                             WITHIN 24h OF MRI
                                    ↓
                    ┌───────────────┴───────────────┐
                    ↓                               ↓
               RADIOTHERAPY                     SURGERY
                    ↓                               ↓
         STABLE + RADIOSENSITIVE     UNSTABLE OR RADIORESISTANT
                    ↓                               ↓
              EBRT 20Gy/5#                DECOMPRESSION
          or SBRT 24Gy/2-3#                    +
                                          STABILISATION
                                               ↓
                                      POST-OP RADIOTHERAPY
                                          (4-6 weeks)

Decision-Making Framework: NOMS

The NOMS Framework (Neurologic-Oncologic-Mechanical-Systemic) provides a systematic approach to treatment selection: [52]

N - Neurologic Assessment (Bilsky ESCC Grade)

• Grade 0-1b: No/minimal cord compression → Radiotherapy safe
• Grade 1c-2: Moderate compression → Surgery if mechanical instability or radioresistant tumor
• Grade 3: High-grade compression → Surgical emergency (decompression within 24h)

Principle: The higher the grade, the more urgent the need for surgical decompression to prevent irreversible cord ischemia.

O - Oncologic Assessment (Radiosensitivity)

Highly Radiosensitive (upfront radiotherapy preferred):

• Lymphoma (Hodgkin and Non-Hodgkin)
• Multiple Myeloma / Plasmacytoma
• Small Cell Lung Cancer
• Germ Cell Tumors
• Neuroblastoma (pediatric)

Moderately Radiosensitive:

• Breast Cancer
• Prostate Cancer
• Non-Small Cell Lung Cancer (adenocarcinoma)

Radioresistant (surgery preferred):

• Renal Cell Carcinoma
• Melanoma
• Hepatocellular Carcinoma
• Sarcoma
• Colorectal Cancer

Principle: If tumor is exquisitely radiosensitive AND spine is stable, avoid surgical morbidity and use radiotherapy as definitive treatment. [53]

M - Mechanical Stability (SINS Score)

• SINS 0-6 (Stable): Radiotherapy safe, no surgical stabilization required
• SINS 7-12 (Indeterminate): Requires spinal surgery assessment; consider prophylactic stabilization if prolonged survival expected
• SINS 13-18 (Unstable): Absolute indication for surgical stabilization

Principle: Radiotherapy destroys bone faster than it heals. Treating an unstable spine with radiotherapy alone leads to progressive collapse, kyphotic deformity, and treatment failure. [54]

Clinical Instability Signs:

• Mechanical pain (worse with movement, relieved by lying still)
• Progressive kyphotic deformity
• Vertebral collapse > 50%
• Bilateral posterior element destruction
• Subluxation/translation on imaging

S - Systemic Assessment (Patient Fitness and Prognosis)

Performance Status (ECOG/Karnofsky):

• ECOG 0-2 (Karnofsky 100-60): Surgery candidate
• ECOG 3-4 (Karnofsky less than 50): Radiotherapy or palliative care

Prognostic Scoring (Tokuhashi Score, Tomita Score, SORG-ML):

• Predicted survival > 3 months: Aggressive treatment justified
• Predicted survival less than 3 months: Palliative radiotherapy or supportive care

Medical Fitness:

• ASA grade 1-3: Generally fit for surgery
• ASA grade 4-5: High perioperative risk, consider non-operative management
• Specific contraindications: Severe cardiopulmonary disease, coagulopathy (correct INR less than 1.4, platelets > 50K before surgery)

Systemic Disease Burden:

• Oligometastatic disease (1-5 metastases): Aggressive local therapy may prolong survival
• Widespread metastatic disease: Palliative intent

---

7. Treatment Modalities

Medical Management: Corticosteroids

Dexamethasone Protocol

Rationale: Reduces vasogenic edema surrounding compressed cord, decreases inflammatory cytokines, stabilizes blood-spinal cord barrier. [55]

Dosing:

• Loading dose: 16mg IV/PO STAT (upon clinical suspicion, before imaging)
• Maintenance: 8mg BD (give morning and lunchtime to avoid insomnia)
• Duration: Continue until definitive treatment (surgery or radiotherapy), then wean over 2-4 weeks

Evidence: Randomized trials show improved neurological outcomes with high-dose steroids (16mg) vs low-dose (4mg), but no benefit > 16mg. Higher doses increase toxicity without additional efficacy. [56]

Adverse Effects:

• GI: Peptic ulcer perforation (give PPI cover: omeprazole 20mg OD)
• Metabolic: Hyperglycemia (monitor glucose, adjust insulin), hypokalemia
• Psychiatric: Insomnia (avoid evening doses), mood changes, psychosis
• Infectious: Increased infection risk (consider PJP prophylaxis if prolonged use > 3 weeks)
• Myopathy: Proximal muscle weakness (may confound neurological exam)

Contraindications (Relative):

• Active GI perforation (use IV hydrocortisone instead)
• Uncontrolled diabetes (use with glucose control)
• Psychosis (use lowest effective dose, consider alternative steroids)

Weaning Schedule (post-radiotherapy):

• Week 1: 8mg BD
• Week 2: 6mg BD
• Week 3: 4mg BD
• Week 4: 2mg BD
• Week 5: 2mg daily
• Week 6: Stop

Surgical Management

Indications for Surgery

Absolute Indications:

1. Spinal instability (SINS ≥13)
2. Bony compression from retropulsed fragment (requires corpectomy)
3. Radioresistant tumor (renal, melanoma, sarcoma, HCC) with high-grade compression
4. Progression on radiotherapy
5. Pathological fracture with neurological deficit

Relative Indications:

1. Unknown primary requiring tissue diagnosis
2. Oligometastatic disease with good prognosis (candidates for aggressive local control)
3. Prior full-dose radiation to affected spinal segment (salvage surgery)
4. High-grade epidural compression (Bilsky 3) in surgical candidate

Contraindications:

1. ECOG 4 (bedbound, unable to tolerate surgery)
2. Life expectancy less than 3 months (surgery morbidity exceeds benefit)
3. Complete paraplegia > 48-72h (irreversible cord injury)
4. Extensive multilevel disease not amenable to surgical stabilization
5. Medical unfitness (severe cardiopulmonary disease, uncorrectable coagulopathy)

Surgical Techniques

Posterior Decompression + Instrumented Fusion (Most Common):

Indications:

• Posterior/posterolateral epidural tumor
• Single-level involvement
• Intact anterior column (no vertebral body destruction > 50%)

Technique:

1. Laminectomy: Remove lamina, spinous process, ligamentum flavum to expose dura
2. Tumor Debulking: Carefully dissect epidural tumor off dural sac using microinstruments (avoid dural breach)
3. Foraminotomy: Decompress nerve roots laterally
4. Instrumentation: Place pedicle screws 2 levels above and 2 levels below (4-6 screw construct)
5. Rod contouring: Lock rods to screws to create rigid construct
6. Bone graft: Decorticate facets, place allograft/autograft for fusion (though most patients don't survive long enough for fusion)

Advantages:

• Familiar posterior approach for most spine surgeons
• Can extend multiple levels
• Lower morbidity than anterior approaches

Disadvantages:

• Cannot address anterior vertebral body tumor (residual tumor anteriorly)
• Destabilizes spine (removing posterior elements), requires instrumentation
• Incomplete decompression if significant anterior compression [57]

Separation Surgery + SBRT (Modern Hybrid Approach):

Concept: Limited decompression creating 2-3mm gap between dura and tumor, allowing safe high-dose stereotactic radiotherapy (SBRT) to residual tumor. Avoids morbidity of extensive tumor resection. [58]

Technique:

1. Limited laminectomy: Only remove bone necessary to access epidural space
2. Tumor separation: Debulk epidural tumor just enough to create CSF space around cord
3. Minimal instrumentation: Short-segment fixation (may avoid instrumentation if spine stable)
4. SBRT: 24Gy in 2-3 fractions delivered 2-4 weeks post-op to residual tumor

Advantages:

• Shorter operative time, less blood loss
• Addresses radioresistant tumor with combined modality
• Better local control than surgery or radiotherapy alone

Disadvantages:

• Requires access to SBRT capability
• Two-stage treatment (surgery + delayed radiotherapy)

Anterior Corpectomy + Cage Reconstruction (Anterior Approach):

Indications:

• Predominant anterior compression (vertebral body collapse, anterior epidural tumor)
• Failed posterior approach
• Cervical spine (easier anterior access)

Technique:

1. Approach: Anterior (transoral C1-C2, anterolateral C3-C7, transthoracic T2-T11, retroperitoneal L1-L5)
2. Corpectomy: Remove entire vertebral body and tumor
3. Cage reconstruction: Place expandable titanium cage or bone graft strut
4. Anterior plate: Additional fixation with screws into adjacent vertebrae

Advantages:

• Direct access to anterior pathology
• Complete tumor removal
• Immediate anterior column reconstruction

Disadvantages:

• Higher morbidity (thoracotomy, laparotomy)
• Risk of vascular injury (aorta, vena cava)
• Longer operative time
• Often requires supplemental posterior instrumentation (360° fusion) [59]

Vertebroplasty / Kyphoplasty (Percutaneous Cement Augmentation):

Indications:

• Painful vertebral metastasis WITHOUT cord compression
• Impending fracture (> 50% involvement, but no collapse or epidural extension)
• Adjunct to decompression for anterior column support

Technique:

1. Percutaneous transpedicular needle placement under fluoroscopy
2. (Kyphoplasty: inflate balloon to create cavity and restore height)
3. Inject polymethylmethacrylate (PMMA) cement into vertebral body
4. Exothermic reaction stabilizes bone within minutes

Advantages:

• Minimally invasive (outpatient procedure)
• Immediate pain relief in 70-90%
• Low complication rate

Contraindications:

• Epidural tumor extension (risk of cement leak into spinal canal causing acute compression)
• Posterior wall destruction
• Active infection [60]

Surgical Outcomes

Ambulatory Preservation:

• Preoperative ambulatory → 85-90% remain ambulatory post-op
• Preoperative non-ambulatory → 35-40% regain ambulation
• Complete paraplegia > 72h → less than 10% recover meaningful function [61]

Perioperative Mortality: 3-10% (varies by patient selection, comorbidities, extent of disease)

Complications:

• Infection (5-15%): Surgical site infection, epidural abscess
• CSF leak / Dural tear (5-10%): May require repair, lumbar drain
• Neurological deterioration (2-5%): Cord injury during manipulation
• Hardware failure (5-10% long-term): Screw loosening, rod breakage (less relevant given limited survival)
• Medical complications: DVT/PE (5%), pneumonia (10%), MI (2%)

Radiotherapy

Conventional External Beam Radiotherapy (cEBRT)

Technique: Multiple low-energy beams converge on spinal target, sparing surrounding tissues.

Standard Fractionation Schemes:

• 20 Gy in 5 fractions (most common): Delivers 4Gy per day over 1 week. Optimal balance of efficacy and convenience. [62]
• 30 Gy in 10 fractions: Used for longer life expectancy (> 6 months), better local control
• 8 Gy in 1 fraction: Palliative, for very poor prognosis (less than 3 months), equivalent pain relief but higher re-treatment rate

Efficacy:

• Pain relief: 60-70% achieve significant improvement
• Neurological improvement: 30-40% of non-ambulatory patients regain ambulation (inferior to surgery in Patchell trial)
• Local control: 60-80% at 1 year

Toxicity:

• Acute: Fatigue, nausea, skin erythema, transient pain flare (10-20%)
• Subacute: Radiation myelopathy (rare less than 1% with proper dosimetry)
• Late: Vertebral compression fracture (15-20%, especially in renal/lytic lesions)

Retreatment: If progression occurs, can re-irradiate if cumulative cord dose less than 50Gy (2Gy equivalent). Risk of myelopathy increases with re-treatment. [63]

Stereotactic Body Radiotherapy (SBRT) / Stereotactic Radiosurgery (SRS)

Technique: High-precision, high-dose radiation delivered in 1-5 fractions using image guidance and robotic positioning (CyberKnife, TrueBeam).

Dose Schemes:

• 24 Gy in 2 fractions (most common spine SBRT)
• 27-30 Gy in 3 fractions
• 16-18 Gy in 1 fraction (SRS)

Indications:

• Radioresistant histologies (renal, melanoma, sarcoma, HCC)
• Oligometastatic disease (1-3 spine lesions, aggressive local control strategy)
• Recurrent disease post-cEBRT (salvage SBRT)
• Post-separation surgery (hybrid approach)

Advantages over cEBRT:

• Higher biologically effective dose (BED 70-100 Gy vs 30-40 Gy with cEBRT)
• Better local control: 80-95% at 1 year (vs 60-70% with cEBRT)
• Shorter treatment time (1-3 visits vs 5-10 visits)

Requirements:

• CSF space: Minimum 2-3mm between tumor and spinal cord (prevents cord dose > 13-14Gy)
• Spinal stability: SINS less than 7 (unstable spines progress during treatment)
• No high-grade compression: Bilsky 0-2 (Grade 3 requires emergency decompression)

Toxicity:

• Vertebral compression fracture: 20-30% (higher than cEBRT due to greater bone ablation)
• Radiation myelopathy: 1-2% (vs less than 1% with cEBRT)
• Pain flare: 30-40% (can be severe, may require hospitalization) [64]

Radiotherapy vs Surgery: The Patchell Trial

Study Design: Landmark RCT published in Lancet 2005. [65]

Population: 101 patients with single-level MSCC, ambulatory or just non-ambulatory, life expectancy > 3 months.

Intervention:

• Arm 1: Direct decompressive surgery (posterior laminectomy + tumor resection + instrumentation) followed by radiotherapy (30Gy/10#)
• Arm 2: Radiotherapy alone (30Gy/10#)

Primary Outcome: Ability to walk after treatment.

Results (trial stopped early due to overwhelming superiority of surgery):

• Ambulation retention: 84% (surgery) vs 57% (RT alone), p=0.001
• Ambulation recovery: 62% (surgery) vs 19% (RT alone), p=0.01
• Median survival: 126 days (surgery) vs 100 days (RT alone), p=0.03
• Opioid use: Lower in surgery group
• Continence: Better preserved in surgery group

Practice Impact: Established combined surgery + radiotherapy as standard of care for single-level MSCC in surgical candidates with radioresistant or mechanically unstable disease. Does NOT apply to radiosensitive tumors (lymphoma, myeloma) or multilevel disease.

---

8. Prognostication

Tokuhashi Score (Revised 2005)

Predicts survival in patients with spinal metastases. Guides decision between aggressive surgery vs palliative radiotherapy. [66]

Total Score: 0-15 points

Interpretation:

• 0-8 points: Expected survival less than 6 months → Palliative radiotherapy or supportive care
• 9-11 points: Expected survival 6-12 months → Palliative excisional surgery + radiotherapy
• 12-15 points: Expected survival > 12 months → Aggressive excisional surgery (en bloc resection if feasible)

Validation: Accurately predicts survival in 80-85% of patients. Particularly accurate for breast, lung, and prostate cancers.

SORG Machine Learning Algorithm

Modern prognostic model using machine learning (random forest algorithm) trained on 1,101 patients. Available as online calculator. [67]

Variables:

• Primary tumor site
• Number of spinal metastases
• Visceral metastases
• Brain metastases
• Ambulatory status
• Prior systemic therapy
• Time from cancer diagnosis to MSCC

Output: 6-week, 3-month, and 1-year survival probabilities with 95% confidence intervals.

Advantages: More accurate than Tokuhashi (AUC 0.79 vs 0.70), continuously updated with new data, accounts for modern systemic therapies.

Factors Influencing Neurological Prognosis

Preoperative Ambulatory Status: Single strongest predictor.

• Ambulatory → 85% remain ambulatory
• Non-ambulatory less than 48h → 60% regain ambulation
• Non-ambulatory > 48h → 35% regain ambulation
• Complete paraplegia > 72h → less than 10% recovery [68]

Severity of Compression (Bilsky Grade):

• Grade 1-2 → 70% favorable neurological outcome
• Grade 3 → 40% favorable outcome (requires emergency decompression)

Rapidity of Onset:

• Slow progression (> 2 weeks) → Better prognosis (collateral circulation develops)
• Acute onset (less than 24h) → Worse prognosis (ischemic injury)

Tumor Histology:

• Radiosensitive (lymphoma, myeloma) → Better outcomes with radiotherapy
• Radioresistant (renal, melanoma) → Require surgery for comparable outcomes

Spinal Level:

• Lumbar (cauda equina) → Better recovery potential (peripheral nerves can regenerate)
• Thoracic → Worse recovery (cord ischemia, narrow canal)
• Cervical → Variable (depends on severity, higher risk of respiratory compromise)

---

9. Complications and Follow-Up

Complications of MSCC

Irreversible Neurological Deficit:

• Paraplegia: 40-50% of patients have permanent loss of ambulation
• Bladder dysfunction: Requires intermittent self-catheterization or indwelling catheter
• Bowel dysfunction: Requires bowel program (stool softeners, suppositories, digital stimulation)
• Sexual dysfunction: Loss of erectile function, ejaculation, sensation

Secondary Complications of Immobility:

• DVT/PE: 10-20% incidence in non-ambulatory cancer patients (use LMWH prophylaxis)
• Pressure ulcers: Sacral and heel ulcers develop within days of immobility (requires pressure-relief mattress, 2-hour turning)
• Pneumonia: Hypostatic pneumonia from prolonged recumbency
• Muscle atrophy: Rapid deconditioning, contractures

Pain Syndromes:

• Neuropathic pain: Deafferentation pain from nerve injury (requires gabapentin/pregabalin, duloxetine)
• Mechanical pain: Persistent pain from spinal instability despite treatment (may require revision surgery)
• Post-radiation pain flare: Transient (1-2 weeks) severe pain exacerbation after SBRT (treat with dexamethasone taper)

Rehabilitation

Inpatient Rehabilitation: Transfer to specialized spinal cord injury unit for:

• Physiotherapy: Core strengthening, gait retraining, transfer training
• Occupational therapy: ADL retraining, adaptive equipment, home modifications
• Bladder management: Intermittent catheterization training, anticholinergics for hyperreflexia
• Bowel program: Scheduled evacuation, digital stimulation
• Psychological support: Adjustment to disability, depression screening

Outpatient Follow-Up:

• Oncology: Systemic therapy for primary malignancy (chemotherapy, hormonal therapy, immunotherapy)
• Spine surgery: Clinical and radiographic follow-up at 6 weeks, 3 months, 6 months (assess instrumentation, tumor progression)
• Radiation oncology: Assess treatment response, late toxicity monitoring
• Palliative care: Symptom management, advance care planning, hospice transition

Surveillance Imaging

MRI Spine:

• Post-radiotherapy: Baseline 3 months, then every 3-6 months for 2 years (assess local control, detect progression)
• Post-surgery: 6 weeks (assess decompression adequacy), 3 months (tumor response), then every 3-6 months
• Indications for urgent imaging: New or worsening pain, neurological deterioration

Challenges in Interpretation:

• Post-radiation changes: Edema, enhancement can mimic tumor progression (use PET-CT or wait 3 months for re-imaging)
• Post-surgical changes: Postoperative hematoma, scar tissue can obscure tumor recurrence (gadolinium helps differentiate)

---

10. Patient Communication

What is Metastatic Spinal Cord Compression?

"Your cancer has spread to the bones in your back. One of these bones has collapsed or the tumor has grown in a way that's putting pressure on your spinal cord - the nerve highway that carries signals from your brain to your legs, bladder, and bowel. This pressure is cutting off the blood supply to the spinal cord, which is why you're experiencing weakness, numbness, or difficulty walking."

Why is this an emergency?

"The spinal cord is extremely sensitive to pressure. Even a few hours of compression can cause permanent damage. Unlike bones and skin, the spinal cord doesn't heal well once it's injured. That's why we need to act very quickly - within 24 hours - to relieve this pressure using either steroids, surgery, or radiation treatment. The goal is to preserve your ability to walk, control your bladder and bowel, and maintain your independence."

Why do I need to lie flat?

"The cancer has weakened the bone in your back like a crumbling building. If you sit up or stand, the weight of your body could cause that weakened bone to collapse completely, which could sever the spinal cord and cause permanent paralysis. By keeping you flat and rolling you like a log when we need to move you, we're protecting your spine until we can stabilize it with metal screws and rods, or shrink the tumor with radiation."

What are my treatment options?

Surgery: "We make an incision in your back, remove the tumor that's pressing on the spinal cord, and insert metal screws and rods to stabilize your spine. This gives immediate relief of pressure and prevents further collapse. The surgery takes 3-4 hours and requires about a week in the hospital. Most patients who can walk before surgery can still walk afterward. After you heal (4-6 weeks), you'll receive radiation to kill any remaining tumor cells."

Radiation therapy: "We use high-energy X-rays to shrink the tumor. You lie flat on a table for 10-15 minutes while the machine delivers treatment. It doesn't hurt, but the tumor takes several days to shrink, so relief is not immediate. You'll have 5 treatments over one week (or sometimes 1-3 treatments with newer high-precision radiation). This works best if your spine is stable and if you have a tumor type that's very sensitive to radiation, like lymphoma or myeloma."

How do we choose?: "It depends on four main factors: (1) How severe is the compression? (2) What type of cancer do you have? (3) Is your spine stable or unstable? (4) What is your overall health and life expectancy? We'll discuss this with a team of specialists - spine surgeons, radiation oncologists, and medical oncologists - to recommend the best treatment for your specific situation."

What is the prognosis?

"This is an honest but difficult conversation. Your prognosis depends on the type of cancer, how much it has spread, and your overall health. On average, patients with metastatic spinal cord compression live 3-12 months, though some patients with more favorable cancers (breast, prostate) live several years with good quality of life. Our immediate goal is to preserve your ability to walk and maintain your independence. About 85% of patients who can walk before treatment will still be able to walk afterward. The most important predictor is how quickly we intervene - which is why we're acting so urgently right now."

What happens after treatment?

"You'll need ongoing cancer treatment (chemotherapy, hormonal therapy, or immunotherapy) to control the disease throughout your body. You'll have regular follow-up with MRI scans every 3-6 months to watch for tumor regrowth. If the tumor comes back in the spine, we can sometimes give additional radiation or repeat surgery. Many patients are able to return home and maintain a good quality of life for months to years. We'll also connect you with palliative care specialists - these are doctors who focus on symptom management and quality of life, not just on treating the cancer."

---

11. Key Examination Questions (Viva Preparation)

Clinical Scenario Questions

Q1: A 68-year-old man with known prostate cancer presents with 2 weeks of worsening thoracic back pain and difficulty walking for 2 days. How do you assess and manage?

Model Answer: "This is suspected metastatic spinal cord compression - an oncological emergency requiring immediate action within 24 hours.

Immediate Management (while awaiting imaging):

1. Immobilization: Flat bed rest, log-roll transfers only
2. High-dose steroids: Dexamethasone 16mg IV/PO STAT, then 8mg BD with PPI cover
3. Urgent MRI whole spine: Within 24 hours (NOT plain X-rays)
4. Alert MSCC service: Multidisciplinary coordinator for expedited pathway

Clinical Assessment:

• History: Onset, progression, pain character (nocturnal/mechanical), sphincter function, cancer treatment history
• Examination: Percussion tenderness, sensory level, motor power, reflexes, Babinski, post-void residual, rectal tone
• Document ambulatory status (critical prognostic indicator)

Investigations:

• MRI whole spine (STIR, T1, T2, T1+Gd): Identify level, assess compression severity (Bilsky grade), check for skip lesions
• Bloods: FBC, U&E, Calcium, PSA
• Consider CT CAP if unknown primary

Treatment Decision (using NOMS framework):

• Neurologic: Bilsky grade? (3 = emergency surgery)
• Oncologic: Prostate is moderately radiosensitive
• Mechanical: SINS score on MRI (> 13 = unstable, needs surgery)
• Systemic: Performance status, prognosis score (Tokuhashi)

Likely Outcome: If single level, SINS > 13, ambulatory → Surgery (posterior decompression + instrumented fusion) followed by post-op radiotherapy. If SINS less than 7, stable → Radiotherapy 20Gy/5 fractions.

Prognostic Counseling: Prostate cancer scores 5 points on Tokuhashi (favorable primary). If Tokuhashi total > 9, expected survival > 6 months, justify aggressive treatment."

---

Q2: Compare and contrast conventional radiotherapy versus stereotactic body radiotherapy (SBRT) for spinal metastases.

Model Answer:

When to use SBRT:

1. Radioresistant histology (renal, melanoma, sarcoma, HCC)
2. Post-separation surgery (hybrid approach)
3. Oligometastatic disease (aggressive local control strategy)
4. Recurrence after prior cEBRT

Contraindications to SBRT:

1. High-grade cord compression (Bilsky 3) - requires emergency surgery
2. No CSF space (less than 2mm between tumor and cord) - risk of myelopathy
3. Spinal instability (SINS > 13) - will progress during treatment
4. Multilevel disease (technically feasible but increased toxicity)"

---

Q3: Describe the Patchell trial and its impact on MSCC management.

Model Answer: "The Patchell trial (Lancet 2005) is the landmark randomized controlled trial that established the role of surgery in MSCC.

Study Design:

• Population: 101 patients with single-level MSCC, ambulatory or recently non-ambulatory, expected survival > 3 months
• Intervention Arm: Direct decompressive surgery (posterior laminectomy + tumor resection + instrumentation) followed by radiotherapy (30Gy/10 fractions)
• Control Arm: Radiotherapy alone (30Gy/10 fractions)
• Primary Outcome: Ability to walk after treatment (≥10 feet with walker/cane)

Results (trial stopped early at interim analysis):

• Ambulation retention: 84% vs 57% (p=0.001)
• Ambulation recovery (in non-ambulatory): 62% vs 19% (p=0.01)
• Median survival: 126 days vs 100 days (p=0.03)
• Secondary outcomes: Surgery group had lower opioid requirements, better bladder/bowel function, fewer deaths from MSCC

Impact on Practice:

1. Established surgery + adjuvant radiotherapy as standard of care for single-level MSCC in surgical candidates
2. Shifted paradigm from "radiotherapy for all" to selective surgery for appropriate patients
3. Demonstrated importance of early surgical referral in ambulatory patients

Limitations/Caveats:

• Single-level disease only: Does NOT apply to multilevel compression (not surgically feasible)
• Excluded radiosensitive tumors: Lymphoma and myeloma patients were excluded (radiation alone remains standard for these)
• Pre-SBRT era: Published before modern stereotactic radiotherapy (SBRT hybrid approaches now emerging)
• Surgical technique evolution: Modern separation surgery may achieve similar outcomes with lower morbidity

Current Application: Use Patchell data to counsel patients, but apply NOMS framework to individualize treatment. Surgery + RT remains gold standard for single-level, radioresistant, unstable MSCC in surgical candidates."

---

Q4: What is the SINS score and how do you use it clinically?

Model Answer: "The Spinal Instability Neoplastic Score (SINS) is a validated 6-component scoring system (0-18 points) that objectively quantifies mechanical stability in patients with spinal metastases. It guides the decision between surgery and radiotherapy.

Six Components (assessed on CT/MRI):

1. Location (0-3 points): Junctional segments (occiput-C2, C7-T2, T11-L1, L5-S1) score highest due to stress concentration
2. Pain (0-3 points): Mechanical pain (worse with movement/loading) indicates instability
3. Bone Lesion Quality (0-2 points): Lytic lesions score higher (destroy bone) vs blastic (preserve strength)
4. Spinal Alignment (0-4 points): Subluxation/translation scores highest, new kyphosis intermediate
5. Vertebral Body Collapse (0-3 points): > 50% height loss scores highest
6. Posterolateral Involvement (0-3 points): Bilateral pedicle/facet destruction scores highest (loss of tension band)

Interpretation:

• 0-6 points (Stable): Radiotherapy safe, no need for prophylactic stabilization
• 7-12 points (Indeterminate): Requires surgical consultation; may need prophylactic fixation if prolonged survival expected
• 13-18 points (Unstable): Absolute indication for surgical stabilization before/instead of radiotherapy

Clinical Application:

1. Pre-radiotherapy assessment: Never radiate an unstable spine (SINS > 13) without surgical stabilization - radiotherapy accelerates bone destruction before stimulating healing, leading to progressive collapse
2. Surgical planning: SINS > 13 requires instrumented fusion regardless of tumor radiosensitivity
3. Risk stratification: SINS 7-12 patients with good prognosis (> 6 months) may benefit from prophylactic stabilization to prevent future surgery

Evidence: Validated in multiple cohorts with 95% inter-observer reliability. Prospective studies show SINS > 13 correlates with 30-50% risk of progression if treated with radiotherapy alone.

Practical Example: Lytic renal cell met in L3 (mobile spine = 2) + mechanical pain (3) + lytic (2) + 60% collapse (3) + bilateral pedicle involvement (3) = SINS 13 → UNSTABLE → Requires surgery regardless of other factors."

---

12. References

1. Cole JS, Patchell RA. Metastatic epidural spinal cord compression. Lancet Neurol. 2008;7(5):459-466. doi:10.1016/S1474-4422(08)70089-9

2. Prasad D, Schiff D. Malignant spinal cord compression. Lancet Oncol. 2005;6(1):15-24. doi:10.1016/S1470-2045(05)70022-X

3. Husband DJ. Malignant spinal cord compression: prospective study of delays in referral and treatment. BMJ. 1998;317(7150):18-21. doi:10.1136/bmj.317.7150.18

4. Rades D, Stalpers LJ, Veninga T, et al. Evaluation of five radiation schedules and prognostic factors for metastatic spinal cord compression. J Clin Oncol. 2005;23(15):3366-3375. doi:10.1200/JCO.2005.04.754

5. Laufer I, Rubin DG, Lis E, et al. The NOMS framework: approach to the treatment of spinal metastatic tumors. Oncologist. 2013;18(6):744-751. doi:10.1634/theoncologist.2012-0293

6. Bilsky MH, Laufer I, Fourney DR, et al. Reliability analysis of the epidural spinal cord compression scale. J Neurosurg Spine. 2010;13(3):324-328. doi:10.3171/2010.3.SPINE09284

7. National Institute for Health and Care Excellence (NICE). Metastatic spinal cord compression in adults: risk assessment, diagnosis and management. Clinical guideline [CG75]. Published November 2008. Updated September 2019.

8. Schiff D, O'Neill BP, Suman VJ. Spinal epidural metastasis as the initial manifestation of malignancy: clinical features and diagnostic approach. Neurology. 1997;49(2):452-456. doi:10.1212/wnl.49.2.452

9. Fisher CG, DiPaola CP, Ryken TC, et al. A novel classification system for spinal instability in neoplastic disease: an evidence-based approach and expert consensus from the Spine Oncology Study Group. Spine. 2010;35(22):E1221-E1229. doi:10.1097/BRS.0b013e3181e16ae2

10. Helweg-Larsen S, Sørensen PS. Symptoms and signs in metastatic spinal cord compression: a study of progression from first symptom until diagnosis in 153 patients. Eur J Cancer. 1994;30A(3):396-398. doi:10.1016/0959-8049(94)90263-1

11. Bayley A, Milosevic M, Blend R, et al. A prospective study of factors predicting clinically occult spinal cord compression in patients with metastatic prostate carcinoma. Cancer. 2001;92(2):303-310.

12. Levack P, Graham J, Collie D, et al. Don't wait for a sensory level--listen to the symptoms: a prospective audit of the delays in diagnosis of malignant cord compression. Clin Oncol. 2002;14(6):472-480. doi:10.1053/clon.2002.0098

13. Helweg-Larsen S. Clinical outcome in metastatic spinal cord compression. A prospective study of 153 patients. Acta Neurol Scand. 1996;94(4):269-275. doi:10.1111/j.1600-0404.1996.tb07064.x

14. Posner JB. Neurologic Complications of Cancer. Philadelphia: FA Davis; 1995.

15. Bilsky MH, Laufer I, Fourney DR, et al. Reliability analysis of the epidural spinal cord compression scale. J Neurosurg Spine. 2010;13(3):324-328.

16. Sorensen S, Helweg-Larsen S, Mouridsen H, Hansen HH. Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial. Eur J Cancer. 1994;30A(1):22-27. doi:10.1016/s0959-8049(05)80011-5

17. Loblaw DA, Perry J, Chambers A, Laperriere NJ. Systematic review of the diagnosis and management of malignant extradural spinal cord compression: the Cancer Care Ontario Practice Guidelines Initiative's Neuro-Oncology Disease Site Group. J Clin Oncol. 2005;23(9):2028-2037.

18. Wong DA, Fornasier VL, MacNab I. Spinal metastases: the obvious, the occult, and the impostors. Spine. 1990;15(1):1-4.

19. Jacobs WB, Perrin RG. Evaluation and treatment of spinal metastases: an overview. Neurosurg Focus. 2001;11(6):e10. doi:10.3171/foc.2001.11.6.11

20. Bach F, Larsen BH, Rohde K, et al. Metastatic spinal cord compression. Occurrence, symptoms, clinical presentations and prognosis in 398 patients with spinal cord compression. Acta Neurochir (Wien). 1990;107(1-2):37-43.

21. Klimo P Jr, Schmidt MH. Surgical management of spinal metastases. Oncologist. 2004;9(2):188-196.

22. Quraishi NA, Gokaslan ZL, Boriani S. The surgical management of metastatic epidural compression of the spinal cord. J Bone Joint Surg Br. 2010;92(8):1054-1060.

23. Tatsui H, Onomura T, Morishita S, Oketa M, Inoue T. Survival rates of patients with metastatic spinal cancer after scintigraphic detection of abnormal radioactive accumulation. Spine. 1996;21(18):2143-2148.

24. Batson OV. The function of the vertebral veins and their role in the spread of metastases. Ann Surg. 1940;112(1):138-149.

25. Algra PR, Bloem JL, Tissing H, Falke TH, Arndt JW, Verboom LJ. Detection of vertebral metastases: comparison between MR imaging and bone scintigraphy. Radiographics. 1991;11(2):219-232.

26. Perrin RG, Laxton AW. Metastatic spine disease: epidemiology, pathophysiology, and evaluation of patients. Neurosurg Clin N Am. 2004;15(4):365-373.

27. Dunn RC Jr, Kelly WA, Wohns RN, Howe JF. Spinal epidural neoplasia. A 15-year review of the results of surgical therapy. J Neurosurg. 1980;52(1):47-51.

28. Siegal T, Siegal T. Current considerations in the management of neoplastic spinal cord compression. Spine. 1989;14(2):223-228.

29. Ushio Y, Posner R, Posner JB, Shapiro WR. Experimental spinal cord compression by epidural neoplasm. Neurology. 1977;27(5):422-429.

30. Delattre JY, Arbit E, Thaler HT, Rosenblum MK, Posner JB. A dose-response study of dexamethasone in a model of spinal cord compression caused by epidural tumor. J Neurosurg. 1989;70(6):920-925.

31. Constans JP, de Divitiis E, Donzelli R, Spaziante R, Meder JF, Haye C. Spinal metastases with neurological manifestations. Review of 600 cases. J Neurosurg. 1983;59(1):111-118.

32. Tarlov IM. Spinal Cord Compression: Mechanisms of Paralysis and Treatment. Springfield, IL: Charles C Thomas; 1957.

33. Fisher CG, DiPaola CP, Ryken TC, et al. A novel classification system for spinal instability in neoplastic disease: an evidence-based approach and expert consensus from the Spine Oncology Study Group. Spine. 2010;35(22):E1221-E1229.

34. Fourney DR, Frang ZA, Abi-Said D, et al. Spinal instability neoplastic score: an analysis of reliability and validity from the spine oncology study group. J Clin Oncol. 2011;29(22):3072-3077.

35. Flynn DF, Shipley WU. Management of spinal cord compression secondary to metastatic prostatic carcinoma. Urol Clin North Am. 1991;18(1):145-152.

36. Rodichok LD, Harper GR, Ruckdeschel JC, et al. Early diagnosis of spinal epidural metastases. Am J Med. 1981;70(6):1181-1188.

37. Gilbert RW, Kim JH, Posner JB. Epidural spinal cord compression from metastatic tumor: diagnosis and treatment. Ann Neurol. 1978;3(1):40-51.

38. Greenberg HS, Kim JH, Posner JB. Epidural spinal cord compression from metastatic tumor: results with a new treatment protocol. Ann Neurol. 1980;8(4):361-366.

39. Maranzano E, Latini P. Effectiveness of radiation therapy without surgery in metastatic spinal cord compression: final results from a prospective trial. Int J Radiat Oncol Biol Phys. 1995;32(4):959-967.

40. Frankel HL, Hancock DO, Hyslop G, et al. The value of postural reduction in the initial management of closed injuries of the spine with paraplegia and tetraplegia. Paraplegia. 1969;7(3):179-192.

41. Shapiro S, Snyder W. Spinal instrumentation with preservation of spinal cord function in metastatic epidural disease. J Neurosurg. 1991;75(4):502-506.

42. Lee TT, Green BA. Surgical treatment of metastatic disease of the cervical spine. Neurosurg Clin N Am. 2004;15(4):429-441.

43. Stark RJ, Henson RA, Evans SJ. Spinal metastases. A retrospective survey from a general hospital. Brain. 1982;105(Pt 1):189-213.

44. Loblaw DA, Laperriere NJ. Emergency treatment of malignant extradural spinal cord compression: an evidence-based guideline. J Clin Oncol. 1998;16(4):1613-1624.

45. Hollis PH, Malis LI, Zappulla RA. Neurological deterioration after lumbar puncture below complete spinal subarachnoid block. J Neurosurg. 1986;64(2):253-256.

46. National Institute for Health and Care Excellence (NICE). Metastatic spinal cord compression in adults: risk assessment, diagnosis and management. CG75. 2008.

47. Bilsky MH, Laufer I, Fourney DR, et al. Reliability analysis of the epidural spinal cord compression scale. J Neurosurg Spine. 2010;13(3):324-328.

48. National Institute for Health and Care Excellence. Metastatic spinal cord compression in adults. NICE guideline CG75. 2008.

49. Katagiri H, Takahashi M, Wakamatsu T, Honda Y, Hiraiwa M, Moriya Y. Determining the site of the primary cancer in patients with skeletal metastasis of unknown origin: a retrospective study. Cancer. 2015;121(22):4006-4012.

50. Van de Pol M, Van Aalst J, Wilmink JT, Twijnstra A. Brain metastases from an unknown primary tumour: which diagnostic procedures are indicated? J Neurol Neurosurg Psychiatry. 1996;61(3):321-323.

51. Ralston SH, Gallacher SJ, Patel U, Campbell J, Boyle IT. Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients. Ann Intern Med. 1990;112(7):499-504.

52. Laufer I, Rubin DG, Lis E, et al. The NOMS framework: approach to the treatment of spinal metastatic tumors. Oncologist. 2013;18(6):744-751.

53. Rades D, Huttenlocher S, Dunst J, et al. Matched pair analysis comparing surgery followed by radiotherapy and radiotherapy alone for metastatic spinal cord compression. J Clin Oncol. 2010;28(22):3597-3604.

54. Tancioni F, Navarria P, Pessina F, et al. Assessment of spinal instability and treatment outcomes in patients with spinal metastases. J Neurosurg Spine. 2016;24(4):587-595.

55. Vecht CJ, Haaxma-Reiche H, van Putten WL, de Visser M, Vries EP, Twijnstra A. Initial bolus of conventional versus high-dose dexamethasone in metastatic spinal cord compression. Neurology. 1989;39(9):1255-1257.

56. Sorensen S, Helweg-Larsen S, Mouridsen H, Hansen HH. Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial. Eur J Cancer. 1994;30A(1):22-27.

57. Wise JJ, Fischgrund JS, Herkowitz HN, Montgomery D, Kurz LT. Complication, survival rates, and risk factors of surgery for metastatic disease of the spine. Spine. 1999;24(18):1943-1951.

58. Laufer I, Iorgulescu JB, Chapman T, et al. Local disease control for spinal metastases following "separation surgery" and adjuvant hypofractionated or high-dose single-fraction stereotactic radiosurgery: outcome analysis in 186 patients. J Neurosurg Spine. 2013;18(3):207-214.

59. Sundaresan N, Rothman A, Manhart K, Kelliher K. Surgery for solitary metastases of the spine: rationale and results of treatment. Spine. 2002;27(16):1802-1806.

60. Berenson J, Pflugmacher R, Jarzem P, et al. Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial. Lancet Oncol. 2011;12(3):225-235.

61. Patchell RA, Tibbs PA, Regine WF, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet. 2005;366(9486):643-648.

62. Rades D, Stalpers LJ, Veninga T, et al. Evaluation of five radiation schedules and prognostic factors for metastatic spinal cord compression. J Clin Oncol. 2005;23(15):3366-3375.

63. Sahgal A, Weinberg V, Ma L, et al. Probabilities of radiation myelopathy specific to stereotactic body radiation therapy to guide safe practice. Int J Radiat Oncol Biol Phys. 2013;85(2):341-347.

64. Ryu S, Pugh SL, Gerszten PC, et al. RTOG 0631 phase 2/3 study of image guided stereotactic radiosurgery for localized (1-3) spine metastases: phase 2 results. Pract Radiat Oncol. 2014;4(2):76-81.

65. Patchell RA, Tibbs PA, Regine WF, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet. 2005;366(9486):643-648.

66. Tokuhashi Y, Matsuzaki H, Oda H, Oshima M, Ryu J. A revised scoring system for preoperative evaluation of metastatic spine tumor prognosis. Spine. 2005;30(19):2186-2191.

67. Schoenfeld AJ, Ferrone ML, Schwab JH, et al. Prospective validation of a clinical prediction score for survival in patients with spinal metastases: the New England Spinal Metastasis Score. Spine J. 2021;21(1):28-36.

68. Patchell RA, Tibbs PA, Regine WF, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet. 2005;366(9486):643-648.

---